Penn Spinout Regenxbio Opens New Gene Therapy Manufacturing Facility in Maryland

Regenxbio, a gene therapy company founded in 2009 through collaboration with the Penn Center for Innovation, opened a new facility at its Maryland campus. The $65 million, 132,000-square-foot gene therapy manufacturing facility will help the company elevate its in-house manufacturing of NAV Technology-based adeno-associated virus, or AAV, vectors and implement their platform suspension cell culture process.

Read the full article here:

Skip to content